

Evaluation of anidulafungin in the treatment of intra-abdominal candidiasis: a pooled analysis of patient-level data from 5 prospective studies

European Journal of Clinical Microbiology & Infectious Diseases

Gabriele Sganga¹ • Minggui Wang² • M. Rita Capparella³ • Margaret Tawadrous⁴ •

Jean L. Yan⁵ • Jalal A. Aram⁴ • Philippe Montravers⁶

¹*Emergency Surgery, Fondazione Policlinico Universitario A. Gemelli IRCCS – Università Cattolica del Sacro Cuore, Roma, Italy;* ²*Fudan University, Shanghai, China;* ³*Pfizer PIO, Paris, France;* ⁴*Pfizer Inc, Groton, CT, USA;* ⁵*Pfizer Inc, Collegeville, PA, USA;* ⁶*Paris Diderot Sorbonne Cite University and Bichat-Claude Bernard University Hospital, Paris, France.*

Correspondence: Dr. Gabriele Sganga, Emergency Surgery, Fondazione Policlinico Universitario A. Gemelli IRCCS – Università Cattolica del Sacro Cuore, Roma, Italy, Largo A. Gemelli 8, 00168 Roma, Italy.

Tel: 063015 4437/6211/4545 (gabriele.sganga@policlinicogemelli.it)

Online Resource 1 *In vitro* MIC data for anidulafungin, and susceptibility to anidulafungin, fluconazole and voriconazole, by *Candida* species

Species (n)	Anidulafungin MIC₅₀ (mg/L)	Anidulafungin MIC₉₀ (mg/L)	Susceptible to anidulafungin (%)	Susceptible to fluconazole (%)	Susceptible to voriconazole (%)
All <i>Candida</i> species (57)	≤0.015	0.03	100.0	84.2	94.7
<i>C. albicans</i> (37)	≤0.015	0.03	100.0	91.9	91.9
<i>C. glabrata</i> (15)	0.03	0.125	100.0	66.7	100.0
<i>C. krusei</i> (1)	0.03	0.03	100.0	0.0	100.0
<i>C. tropicalis</i> (4)	≤0.015	0.03	100.0	100.0	100.0

MIC, minimum inhibitory concentration